萝莉社

Skip to main content
(904) 244-0411

A Phase 1 Study of EG-70 as an Intravesical Administration to Patients with BCG -Unresponsive NMIBC

  • Status
    Accepting Candidates
  • Age
    18 Years - 101 Years
  • Sexes
    All
  • Healthy Volunteers
I'm interested
Share this study

Description

聽 A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG -Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Na茂ve or Received Incomplete BCG Treatment

Phase 1: The purpose of this study is to evaluate the safety and tolerability of escalating dose levels of Eg-70 administered by intravesical instillation in patients with Bcg-unresponsive Nmibc who are scheduled for, refuse, or are ineligible for radical cystectomy

Phase 2: the purpose of this study is to evaluate the efficacy of Eg-70 (determined by complete response) at 48 weeks in each cohort separately. To evaluate the safety of the Rp2D of Eg-70 administered by intravesical instillation in patients with Bcg-unresponsive Nmibc and patients with high-risk Nmibc who are Bcg na茂ve or have received incomplete Bcg treatment

Details

Protocol number EG-70-101

Eligibility

Inclusion Criteria:聽 BCG-Unresponsive Patients (Phase 1 and Phase 2-Cohort 1):

  1. BCG Unresponsive NMIBC with CIS of the bladder who are ineligible for or have elected not to undergo cystectomy, and have experienced a) persistent disease within 12 months of treatment or b) a recurrence within 6 months of completion of adequate BCG therapy BCG-Naive or BCG-incompletely Treated Patients (Phase 2-Cohort 2 only):
  2. NMIBC with current CIS of the bladder, who are ineligible for or have elected not to undergo cystectomy where either a) incomplete BCG (at least 1 dose) treatment or b) no treatment with BCG but who have previously been treated with at least 1 dose of intravesical chemotherapy following transurethral resection of bladder tumor (TURBT) and CIS must be documented or indicated by pathology within 4 months of or at screening
  3. Aged 18 years of age or older
  4. Performance Status: ECOG 0-2 Exclusion Criteria:聽
  5. Concurrent treatment with any chemotherapeutic agent
  6. Evidence of persistent or ongoing renal failure
  7. Evidence of metastatic disease 聽

Lead researcher

Participate in a study

Here are some general steps to consider when participating in a research study:

  1. Step
    1

    Contact the research team

    Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.

    Primary contact

  2. Step
    2

    Get screened to confirm eligibility

    You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.

  3. Step
    3

    Provide your consent to participate

    If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.

  4. Step
    4

    Participate

    If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.